Results 71 to 80 of about 47,826 (189)

Transcriptome‐Based Classification of Resected Pancreatic Ductal Adenocarcinoma Enhances Prognostic Modelling Accuracy of Overall Survival Following Adjuvant Treatment

International Journal of Cancer, Volume 159, Issue 5, Page 1322-1336, 1 September 2026.
Outcomes after resection of pancreatic ductal adenocarcinoma remain highly variable, and existing prognostic models lack sufficient accuracy. Here, the authors aimed to improve survival prediction by integrating transcriptome‐based subtyping into a validated clinical model and applying it to a multicenter real‐world cohort of fresh‐frozen resection ...
Marjolein F. Lansbergen, Vincent R. Lanting, Paul Manoukian, Marc G. Besselink, Geert Kazemier, Ignace H. J. T. de Hingh, Mike S. L. Liem, Casper H. J. van Eijck, Erwin van der Harst, Vincent E. de Meijer, Ronald M. van Dam, Martijn W. J. Stommel, Jan Koster, Michael W. T. Tanck, Arantza Fariña Sarasqueta, Joanne Verheij, Frederike Dijk, Johanna W. Wilmink, Maarten F. Bijlsma, Hanneke W. M. van Laarhoven, for the Dutch Pancreatic Cancer Group   +20 more
wiley   +1 more source

Clinical Efficacy of Neoadjuvant Camrelizumab Plus Chemotherapy for Triple‐Negative Breast Cancer and Tumor Immune Microenvironment Analysis: A Prospective‐Retrospective Cohort Study

MedComm, Volume 7, Issue 9, September 2026.
Cohort Study Design:Between January 2019 and July 2023, 276 stage II‐III TNBC patients were enrolled in this study, including 56 in the NIC cohort and 220 in the NAC cohort. Due to 17 cases of ineligible criteria, 5 with withdrawal of informed consent, 198 patients in the NAC cohort completed NAC and underwent surgical resection.
Yongsheng Wang, Pengfei Qiu, Yuechen Wang, Xingchen Meng, Jiaxin Zhang, Haiqiang Liu, Zhiqiang Shi, Zhaopeng Zhang, Xiao Sun, Chunjian Wang, Xiangjing Meng, Chunhui Zheng   +11 more
wiley   +1 more source

Clinical observation of capecitabine in the maintenance treatment of advanced breast cancer

Zhongguo aizheng zazhi, 2014
Background and purpose: Capecitabine, which is widely used in the first-line treatment of advanced breast cancer, was known little in the maintenance treatment of advanced breast cancer.
李剑英, 季从飞, 陈佳, 谭清和
doaj  

Photosensitive lichenoid skin reaction to capecitabine

BMC Cancer, 2017
Background Capecitabine is an oral prodrug of fluorouracil, which is a common agent used in the management of many solid tumor malignancies. Dermatologic reaction is common with various chemotherapy agents but is not commonly reported in the use of ...
Rena A. Shah, Daniel D. Bennett, Mark E. Burkard   +2 more
doaj   +1 more source

Eccrine Squamous Syringometaplasia Mimicking Acute Cutaneous GVHD in a Pediatric HSCT Recipient: Case Report and Brief Review of the Indexed Literature

Journal of Cutaneous Pathology, Volume 53, Issue 9, Page 792-802, September 2026.
ABSTRACT Eccrine squamous syringometaplasia (ESS) is an uncommon reactive alteration of eccrine ducts, most often reported in oncologic and transplant settings, where it may clinically mimic acute cutaneous graft‐versus‐host disease (GVHD). We describe a 3‐year‐old boy with chronic granulomatous disease who developed a diffuse erythematous eruption 6 ...
Benedetta Galli, Cecilia Catapano, Iacopo Ghini, Mariateresa Rossi, Marina Venturini, Valeria Boccaletti   +5 more
wiley   +1 more source

Capecitabine-induced cicatricial ectropion: A case review

The Pan-American Journal of Ophthalmology
Capecitabine, an oral prodrug of 5-fluorouracil (5-FU), offers a more targeted chemotherapeutic approach, reducing systemic side effects. However, cases of ocular side effects have been described in the literature. We report the case of a 94-year-old man
Stuti Misty Tanya, Andrea Dahoud, Ahmed Al-Amer, Bryan Arthurs, Christian El-Hadad   +4 more
doaj   +1 more source

Ixabepilone as Monotherapy or in Combination with Capecitabine for the Treatment of Advanced Breast Cancer

Breast Cancer: Basic and Clinical Research, 2011
Breast Cancer is the most prevalent cancer in the world with 4.4 million survivors up to 5 years following the diagnosis. 1 In the US alone approximately forty thousand women die annually of metastatic breast cancer (MBC). Despite many effective systemic
Katherine H. Rak Tkaczuk
doaj   +1 more source

High‐Throughput Digital Decoding of Vascular Heterogeneity in Patient‐Specific Tumor Microenvironments

Advanced Healthcare Materials, Volume 15, Issue 29, 7 August 2026.
ABSTRACT Quantitative characterization of vascular heterogeneity in complex microphysiological systems (MPS), particularly within patient‐derived tumor microenvironments, remains a major challenge for scalable disease modeling and therapeutic evaluation.
Jungseub Lee, Wooju Park, Sujin Hyung, Sangmin Jung, Kyungho Lee, Junseok Jeon, Noo Li Jeon, Jeeyun Lee, Hye Ryoun Jang, Jihoon Ko   +9 more
wiley   +1 more source

Low‐Dose Antiangiogenic Therapy With Different Chemotherapy Backbones Among Patients With Heavily Pretreated Metastatic Breast Cancer

Cancer Innovation, Volume 5, Issue 4, August 2026.
Antiangiogenic‐based regimens demonstrated superior efficacy compared to chemotherapy alone in heavily pretreated MBC patients, with manageable AEs. ABSTRACT Background The prognosis for metastatic breast cancer (MBC) remains poor, and treatment options are limited for patients with heavily pretreated disease. Although antiangiogenic agents may provide
Yuanyi Wang, Yalong Qi, Cheng Zeng, Ruixia Song, Yuhan Wei, Haili Qian, Fei Ma   +6 more
wiley   +1 more source

A Phase I/II Study of Ibrutinib Plus Trastuzumab in HER2‐Positive Metastatic Breast Cancer

Cancer Medicine, Volume 15, Issue 8, August 2026.
ABSTRACT Ibrutinib has demonstrated inhibition of ErbB/HER tyrosine kinases in preclinical models. This Phase I/II study investigated the safety, efficacy, and immunomodulatory effects of ibrutinib in combination with trastuzumab in patients with HER2‐positive metastatic breast cancer (MBC) whose disease had progressed on ado‐trastuzumab emtansine ...
Joyce O'Shaughnessy, Andrea Glidden, Tracy Locke, Amy Scales, Elizabeth Gatewood, Jean‐Philippe Blanck, Jessica Castaneda‐Gill, Sharlin Patel, Yolanda D. Mahnke, Xuan Wang, Page Blas   +10 more
wiley   +1 more source